| Novel Aptamers to Target Metastasis |
Nov 2012 |
21 pages |
| Authors:
Evan Keller; Greg Shelley; MICHIGAN UNIV ANN ARBOR
|
 | Metastasis and tumor progression at metastatic sites ultimately results in the demise of prostate cancer (PCa) patients. Currently there are no highly effective methods that can target these problems. Aptamers, which have proven clinical efficacy for non-neoplastic disease and are generally more specific and stable than antibodies, may have clinical utility in PCa. However, defining aptamers that can prevent metastasis is challenging due to the fact that many proteins that ... |
|
| Novel Aptamers to Target Metastasis |
Sep 2011 |
11 pages |
| Authors:
Evan Keller; MICHIGAN UNIV ANN ARBOR
|
| Metastasis and tumor progression at metastatic sites ultimately results in the demise of prostate cancer (PCa) patients. currently there are no highly effective methods that can target these problems. Aptamers, which have proven clinical efficacy for non-neoplastic disease and are generally more specific and stable than antibodies, may have clinical utility in PCa. However, defining apatamers that can prevent metastasis is challenging due to the fact that many proteins that ... |
|
| Novel Aptamers to Target Metastasis |
SEP 2010 |
9 pages |
| Authors:
Evan Keller; MICHIGAN UNIV ANN ARBOR
|
| The overall goal of this project is to develop novel method to inhibit cancer metastasis. The major hypothesis to be tested is that aptamers (short oligonucleotides) can be developed that target the process of invasion, without prior knowledge of a target protein, and that these aptamers will inhibit the development of metastasis. We have identified two aptamers (Mod 12 and Mod 13) using a novel application of a process called ... |
|
Reports by Author
